Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E15.16 EPS (ttm)5.20 Insider Own0.20% Shs Outstand748.30M Perf Week0.92%
Market Cap58.97B Forward P/E7.71 EPS next Y10.23 Insider Trans-4.31% Shs Float722.36M Perf Month1.47%
Income4.12B PEG0.77 EPS next Q2.09 Inst Own78.30% Short Float4.75% Perf Quarter-7.27%
Sales13.58B P/S4.34 EPS this Y109.10% Inst Trans-5.70% Short Ratio4.98 Perf Half Y-27.22%
Book/sh6.91 P/B11.40 EPS next Y20.00% ROA- Target Price112.98 Perf Year-41.05%
Cash/sh6.33 P/C12.44 EPS next 5Y19.56% ROE- 52W Range74.13 - 147.17 Perf YTD-24.49%
Dividend- P/FCF- EPS past 5Y25.80% ROI20.00% 52W High-46.46% Beta1.43
Dividend %- Quick Ratio2.40 Sales past 5Y18.70% Gross Margin96.40% 52W Low6.30% ATR1.62
Employees7467 Current Ratio2.50 Sales Q/Q19.40% Oper. Margin- RSI (14)44.92 Volatility1.84% 1.77%
OptionableYes Debt/Eq3.92 EPS Q/Q-4.20% Profit Margin- Rel Volume0.58 Prev Close79.14
ShortableYes LT Debt/Eq3.92 EarningsMay 04 BMO Payout- Avg Volume6.90M Price78.80
Recom2.30 SMA200.34% SMA50-4.82% SMA200-22.66% Volume4,029,277 Change-0.43%
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-22-18 03:06PM  Celgene sues pharma with Durham ops American City Business Journals
07:00AM  2 Incredibly Cheap Value Stocks to Buy Now Motley Fool
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
06:30AM  Why I'm Bullish on the Riskiest Big Biotech Stock on the Market Motley Fool
Jun-19-18 04:30PM  Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi Business Wire
04:02PM  5 Top Stock Trades for Wednesday Morning InvestorPlace
01:25PM  CVS will offer home delivery of prescriptions Yahoo Finance Video
08:16AM  Better Buy: Celgene Corporation vs. Merck Motley Fool
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-17-18 12:03PM  Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool
Jun-15-18 07:03PM  Cramer's lightning round: Tandem Diabetes is one of the h... CNBC Videos
06:49PM  Cramer's lightning round: Tandem Diabetes is one of the hottest stocks I've ever seen CNBC
10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
09:46AM  Should You Buy Celgene Stock? Motley Fool
09:11AM  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant Zacks
Jun-14-18 08:20AM  Report: Developing Opportunities within Equinix, Sonus Networks, Celgene, National Grid, Atlas Air Worldwide, and Copa Holdings, S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-13-18 12:00AM  [$$] Celgene admits self-inflicted error over MS drug Financial Times
Jun-12-18 08:42AM  The Zacks Analyst Blog Highlights: Disney, Caterpillar, MetLife, Celgene and Northrop Grumman Zacks
Jun-11-18 06:01PM  Ex-Juno leader becomes CEO of Alder BioPharmaceuticals ahead of migraine drug launch American City Business Journals
11:43AM  Top Research Reports for Disney, Caterpillar & MetLife Zacks
07:38AM  The Cheapest Drug Stocks to Buy Right Now Motley Fool
Jun-08-18 05:01PM  Big News Is Fast Approaching for Celgene Motley Fool
Jun-07-18 05:36PM  Should You Stick With Gilead Sciences? Motley Fool
Jun-06-18 03:24PM  Menendezs Grip on Senate Seat Loosens After Punishing New Jersey Primary Bloomberg
11:37AM  GOP ex-drug CEO hopes centrism and New Jersey roots will help him beat Democratic Sen. Bob Menendez CNBC
08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 07:23AM  3 Reasons Amazing Isn't Good Enough for This Biotech Stock Motley Fool
Jun-04-18 05:26PM  Charts point to big biotech breakout CNBC
04:16PM  Could Celgene Shake Up the CAR-T Market? Motley Fool
04:04PM  Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst Zacks
02:13PM  Here's Why Jounce Therapeutics Fell Over 38% Today Motley Fool
11:37AM  Nektar Roiled by Cancer Data, Other Biotechs Gain Barrons.com
10:37AM  The Probable Reason Behind NovoCure's Double-Digit Drop Today Motley Fool
10:07AM  Meet the GOP former drug CEO spending millions to unseat scandal-plagued Democratic Sen. Menendez in blue New Jersey CNBC
09:38AM  Bluebird Bio shares lift 9% on CAR-T cancer therapy results MarketWatch
08:32AM  Celgene CEO: We don't have to be No. 1 to thrive with new cancer therapy to replace chemo CNBC
08:20AM  Today's Research Reports on Trending Tickers: Exelixis and Celgene ACCESSWIRE
07:15AM  Celgene CEO: There's nothing like pipeline success to rev... CNBC Videos
04:40AM  Celgene (CELG) Down 7.9% Since Earnings Report: Can It Rebound? Zacks
Jun-03-18 07:27PM  The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines Benzinga
12:09PM  Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO Business Wire
10:45AM  Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018 Business Wire
07:18AM  Better Buy: Biogen Inc. vs. Celgene Motley Fool
Jun-01-18 07:07PM  Cramer's lightning round: I think GE's shares are bottomi... CNBC Videos
06:59PM  Cramer's lightning round: I think GE's shares are bottoming CNBC
05:57PM  Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
05:57PM  Bluebird myeloma treatment delays cancer progression-trial Reuters
04:40PM  Conquering cancer in the Windy City CNBC Videos
04:00PM  Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma Business Wire
08:44AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
08:17AM  4 Things Celgene's CEO Just Said That You'll Really Want to Know Motley Fool
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:30PM  Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy Officer Business Wire
01:42PM  ASCO Conference Preview: Here's What Biotech Investors Need to Watch Motley Fool
10:21AM  2018 ASCO Conference Roundup Motley Fool
May-30-18 02:16PM  The Long Decline in Celgene Stock Could Finally Be Over TheStreet.com
11:43AM  Biotech ETFs Are the Best Way to Play the Recovering Sector InvestorPlace
09:17AM  5 Best-Selling Orphan Drugs in the U.S. Motley Fool
08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
May-29-18 01:33PM  The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG) Business Wire
10:47AM  DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG) GlobeNewswire
10:05AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $500K of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
May-28-18 10:50PM  CELGENE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Celgene Corporation - CELG Business Wire
May-26-18 11:07AM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-25-18 10:50PM  CELGENE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Celgene Corporation - CELG Business Wire
03:46PM  CELGENE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Celgene Corporation To Contact The Firm PR Newswire
03:13PM  DEADLINE TUESDAY: INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - CELG ACCESSWIRE
02:07PM  Celgene Hammered, Again, On 'Subpar' Success In Developing Drugs Investor's Business Daily
10:45AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $500K of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
May-24-18 11:58PM  [$$] Celgenes Buybacks Are Coming Up Empty The Wall Street Journal
07:36PM  $100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG) GlobeNewswire
04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
11:23AM  [$$] Celgene's Buybacks Are Coming Up Empty The Wall Street Journal
11:14AM  Celgene Corporation -- Moody's: Celgene's accelerated share repurchase credit negative Moody's
11:07AM  Will Right to Try Bill Boost Biotech ETFs? ETF Trends
09:43AM  Oil Drags On Opening Trade; Dow Lags, Celgene Surges Investor's Business Daily
09:18AM  Celgene Shares Rise on Plans to Increase Stock Buybacks TheStreet.com
08:51AM  I Just Bought My First New Stock in 8 Months, and This Is It Motley Fool
07:34AM  Celgene shares jump 1.2% premarket on news of additional $3 billion share buyback MarketWatch
07:30AM  Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program Business Wire
06:31AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
May-23-18 04:24PM  Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges Investor's Business Daily
03:00PM  CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 GlobeNewswire
09:56AM  David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off? Motley Fool
09:34AM  Celgene Wins One Bull, Loses Another On Revlimid Potential Benzinga
09:26AM  Celgene Cratering to Four-Year Low Leaves Analysts Split Bloomberg
09:15AM  Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It Motley Fool
May-22-18 07:18PM  The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG) Business Wire
05:42PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm GlobeNewswire
04:20PM  Why Amgen's In Trouble And Should Take Notes From Biogen, Celgene Investor's Business Daily
01:52PM  Celgene Corporation: How to Effectively Buy Into CELG Stock InvestorPlace
11:59AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 CELG GlobeNewswire
11:42AM  Celgene Forges Oncology Partnership With Germany's Evotec Benzinga
10:25AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
08:56AM  Reviewing 5 Winning Stocks for a Thinking World, and Relishing 1 Thoughtful CEO Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: Celgene and Foundation Medicine ACCESSWIRE
08:00AM  FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq:CELG) To Contact The Firm GlobeNewswire
07:30AM  Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018 Business Wire
06:33AM  Celgene Strikes Strategic Partnership With Evotec Investopedia
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM